Abstract Gemcitabine (2′, 2′-difluorodeoxycytidine, Gemzar®) is a deoxycytidine analog
with pronounced antitumor activity against a variety of solid tumors, such as non-small cell …

Gemcitabine (dFdC, 2', 2'-difluorodeoxycytidine) is a deoxycytidine nucleoside analogue of
deoxycytidine in which two fluorine atoms have been inserted into the deoxyribose ring. Like …

Summary Synopsis Gemcitabine [2′-deoxy-2′, 2′-difluorocytidine monohydrochloride (β
isomer); dFdC] is a novel deoxycytidine analogue which was originally investigated for its …

Gemcitabine (2′, 2′-difluoro 2′-deoxycytidine, dFdC) is the most important cytidine
analogue developed since cytosine arabinoside (Ara-C). The evidence of its potent …

Abstract Gemcitabine (2 I, 2 I-difluorodeoxycytidine, dFdC) is a nucleoside analogue of
deoxycytidine in which two fluorine atoms have been inserted into the deoxyribofuranosyl …

Gemcitabine (dFdC) is a new anticancer nucleoside that is an analog of deoxycytidine. It is a
pro-drug and, once transported into the cell, must be phosphorylated by deoxycytidine …

Gemcitabine is a nucleoside analog which exhibits metabolic characteristics that distinguish
it from related compounds and may explain its activity in solid tumors. The active nucleotide …

The inherent or induced resistance of tumors to cytostatic agents is a major clinical problem.
In this review, we summarize the pre-clinical mechanisms of acquired and inherent …

Gemcitabine is a deoxycytidine (dCyd) analogue with activity against several solid cancers.
Gemcitabine is activated by dCyd kinase (dCK) and interferes, as its triphosphate dFdCTP …

Gemcitabine (2', 2'-difluorodeoxycyti-dine, dFdC) is an analog of deoxycytidine. It is
transformed to the active triphosphate (dFdCTP) after intracellular phosphorylation …